Rexulti

Chemical Namebrexpiprazole
Dosage FormTablet (oral; 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg)
Drug ClassAntipsychotics
SystemNervous
CompanyOtsuka Pharm Co Ltd
Approval Year2015

Indication

  • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
  • Treatment of schizophrenia.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rexulti (brexpiprazole) Prescribing Information 2018Otsuka America Pharmaceutical, Inc., Rockville, MD